Skip to main content
. 2017 Apr 25;2017(4):CD004197. doi: 10.1002/14651858.CD004197.pub5

Comparison 4. Nebulised tobramycin 28 days versus 56 days.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Time to next isolation of P aeruginosa from BAL, sputum or oropharyngeal cultures 1   Hazard Ratio (Fixed, 95% CI) Totals not selected
2 Number of respiratory exacerbations 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
2.1 Until recurrence of P. aeruginosa 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (up to 3 months) 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
3.1 Cough 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Productive cough 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Haemoptysis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Rhinitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Sinusitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Nasopharyngitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Tonsilitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Oropharyngeal pain 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Dysphonia 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Headache 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 URTI 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Lung disorder 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Bronchitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 P. aeruginosa infection 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Influenza 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Otitis media 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Deafness 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.18 Drug level increased 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.19 Pyrexia 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.20 Vomiting 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.21 Varicella 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (over 3 months) 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
4.1 Cough 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Productive cough 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Haemoptysis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Rhinitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Sinusitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Nasopharyngitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Tonsilitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Oropharyngeal pain 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Dysphonia 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Headache 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 URTI 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Lung disorder 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.13 Bronchitis 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.14 P. aeruginosa infection 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 Influenza 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Otitis media 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.17 Deafness 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.18 Drug level increased 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.19 Pyrexia 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.20 Vomiting 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.21 Varicella 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]